These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 35306855)

  • 1. Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment.
    Londres HD; Armada JJ; Martínez AH; Abdo Cuza AA; Sánchez YH; Rodríguez AG; Figueroa SS; Llanez Gregorich EM; Torres Lahera ML; Peire FG; González TM; González YZ; Añé Kouri AL; Palomo AG; Concepción MT; Pérez LM; Luaces-Alvarez PL; Iglesias DE; Hernández DS; Suzarte MR; Ramos TC
    Immunotherapy; 2022 May; 14(7):521-530. PubMed ID: 35306855
    [No Abstract]   [Full Text] [Related]  

  • 2. Nimotuzumab for COVID-19: case series.
    Abdo Cuza AA; Ávila JP; Martínez RM; González JJ; Aspuro GP; Gutiérrez Martínez JA; Suzarte MR; Hernández DS; Añé-Kouri AL; Ramos TC
    Immunotherapy; 2021 Nov; ():. PubMed ID: 34806405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nimotuzumab Increases the Recovery Rate of Severe and Critical COVID-19 Patients: Evaluation in the Real-World Scenario.
    Diaz H; Jiménez J; Hernández A; Valdés L; Martínez A; Porto L; Hernández R; Travieso N; Jova JH; Medel L; Troche M; Gorte A; Batista D; Valls AR; Cabrera L; Domeq M; Pérez L; Lorenzo-Luaces P; Sánchez L; Saavedra D; Ramos M; Crombet T
    Front Public Health; 2022; 10():948520. PubMed ID: 35937253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune, inflammatory and prothrombotic parameters in COVID-19 patients treated with an anti EGFR antibody.
    Saavedra D; Añé-Kourí AL; Gregorich EML; Mena J; Lorenzo-Luaces P; Londres HD; Martínez AH; Armada JJ; Sánchez YH; González YZ; Troche M; Medel L; Ramos M; Crombet T
    Immunol Lett; 2022 Dec; 251-252():1-8. PubMed ID: 36174772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.
    Solomón MT; Selva JC; Figueredo J; Vaquer J; Toledo C; Quintanal N; Salva S; Domíngez R; Alert J; Marinello JJ; Catalá M; Griego MG; Martell JA; Luaces PL; Ballesteros J; de-Castro N; Bach F; Crombet T
    BMC Cancer; 2013 Jun; 13():299. PubMed ID: 23782513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of malignant, non-resectable, epithelial origin esophageal tumours with the humanized anti-epidermal growth factor antibody nimotuzumab combined with radiation therapy and chemotherapy.
    Ramos-Suzarte M; Lorenzo-Luaces P; Lazo NG; Perez ML; Soriano JL; Gonzalez CE; Hernadez IM; Albuerne YÁ; Moreno BP; Alvarez ES; Callejo IP; Alert J; Martell JA; Gonzalez YS; Gonzalez YS; Astudillo de la Vega H; Ruiz-Garcia EB; Ramos TC
    Cancer Biol Ther; 2012 Jun; 13(8):600-5. PubMed ID: 22555809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
    Kim SH; Shim HS; Cho J; Jeong JH; Kim SM; Hong YK; Sung JH; Ha SJ; Kim HR; Chang H; Kim JH; Tania C; Cho BC
    Lung Cancer; 2013 Mar; 79(3):270-5. PubMed ID: 23261229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile.
    Garrido G; Tikhomirov IA; Rabasa A; Yang E; Gracia E; Iznaga N; Fernández LE; Crombet T; Kerbel RS; Pérez R
    Cancer Biol Ther; 2011 Feb; 11(4):373-82. PubMed ID: 21150278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
    Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
    Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetic Evaluation of Nimotuzumab in Patients With Autosomal Dominant Polycystic Kidney Disease.
    de Castro-Suárez N; Rodríguez-Vera L; Villegas C; Dávalos-Iglesias JM; Bacallao-Mendez R; Llerena-Ferrer B; Leyva-de la Torre C; Lorenzo-Luaces P; Troche-Concepción M; Ramos-Suzarte M
    J Clin Pharmacol; 2019 Jun; 59(6):863-871. PubMed ID: 30633365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer.
    Strumberg D; Schultheis B; Scheulen ME; Hilger RA; Krauss J; Marschner N; Lordick F; Bach F; Reuter D; Edler L; Mross K
    Invest New Drugs; 2012 Jun; 30(3):1138-43. PubMed ID: 21170759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
    Chaccour C; Ruiz-Castillo P; Richardson MA; Moncunill G; Casellas A; Carmona-Torre F; Giráldez M; Mota JS; Yuste JR; Azanza JR; Fernández M; Reina G; Dobaño C; Brew J; Sadaba B; Hammann F; Rabinovich R
    Trials; 2020 Jun; 21(1):498. PubMed ID: 32513289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-escalation phase I trial of nimotuzumab, an antibody against the epidermal growth factor receptor, in patients with advanced solid malignancies.
    You B; Brade A; Magalhaes JM; Siu LL; Oza A; Lovell S; Wang L; Hedley DW; Nicacio LV; Chen EX
    Invest New Drugs; 2011 Oct; 29(5):996-1003. PubMed ID: 20454832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients.
    Wang Y; Pan L; Sheng XF; Chen S; Dai JZ
    Asia Pac J Clin Oncol; 2016 Mar; 12(1):e23-9. PubMed ID: 24571331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [
    Chan C; Fonge H; Lam K; Reilly RM
    Nucl Med Biol; 2020; 80-81():37-44. PubMed ID: 31706737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
    Kim HR; Jang JS; Sun JM; Ahn MJ; Kim DW; Jung I; Lee KH; Kim JH; Lee DH; Kim SW; Cho BC
    Oncotarget; 2017 Feb; 8(9):15943-15951. PubMed ID: 27823977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical Evaluation of
    Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
    J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR.
    Basavaraj C; Sierra P; Shivu J; Melarkode R; Montero E; Nair P
    Cancer Biol Ther; 2010 Oct; 10(7):673-81. PubMed ID: 20647773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.